- SMS Pharmaceuticals is a maker of Active Pharmaceutical Ingredients - the biologically active raw materials inside every generic pill, injection or syrup - selling to drug companies in more than 75 countries. Since its inception in 1990, it grew from a single-product manufacturer into a research-driven enterprise with 55-plus APIs across 14 therapeutic areas. The recurring approach that explains the company is a cycle of backward integration to control raw-material costs, deep R&D investment to build a pipeline of complex, hard-to-copy molecules, and a deliberate tilt toward regulated markets - the US, Europe, Japan - where switching suppliers is difficult and pricing holds firmer.
Business segments
A single engine - API manufacturing - that spans commodity molecules run at enormous scale and high-value niche therapies protected by process patents and regulatory filings, with two emerging platforms still under construction.
1. API manufacturing: the factory that makes the active ingredient inside the medicine
It develops, makes and sells the raw active molecules that generic drug companies turn into finished medicines, earning on every kilogram shipped - and roughly 88% of that revenue comes from regulated markets where quality hurdles keep competition in check.
- Backward-integrated to the intermediate - around 80% of the chemical intermediates consumed in-house are made by the company itself, and only about 10% of raw material is sourced from China, so input costs are largely under its own control rather than at the mercy of import prices.
- Scale that rivals cannot easily match - its dedicated Ibuprofen plant in Visakhapatnam runs a single-block batch size of roughly 10,000 kg, described as the industry’s largest, and current installed capacity of 500 metric tons per month is being expanded to 800 metric tons through a brownfield project expected to finish in FY27.
- A portfolio balanced between volume and value - high-volume products such as Ibuprofen (anti-inflammatory), Tenofovir (anti-retroviral) and Famotidine (anti-ulcer) provide utilisation and cash flow, while high-value molecules like Sitagliptin, Empagliflozin and Dapagliflozin (anti-diabetic), Sumatriptan and Rizatriptan (anti-migraine), and Tadalafil and Sildenafil (anti-erectile dysfunction) contributed 47% of revenue in FY26, up from 30% in FY21.
- Regulatory filings as a moat - the company has submitted over 120 Drug Master Files (DMFs) and owns over 35 process patents; each filing locks in a product with a customer because switching an approved API source in a regulated market requires re-validation, which is slow and expensive.
- Market-share positions in niche molecules - it commands a 40% global market share by value for the anti-anginal API Ranolazine, a 40% share in Europe for the anti-diabetic API Sitagliptin, and up to 100% market share in individual countries such as Mexico, Japan and parts of Europe for certain anti-migraine Triptan molecules.
Group structure and partners
The listed parent sits atop a web of subsidiaries and an associate that extend its reach from peptides to finished formulations, plus a joint venture that gave it first-mover advantage in European anti-diabetics.
- A formulations bridge through an associate - SMS Pharmaceuticals holds 34.83% of VKT Pharma Private Limited, a formulations and pellets manufacturer, with the remaining stake held by promoters, giving the group control over the entire chain from API to finished drug product; VKT Pharma has cleared a USFDA audit and contributed INR 14 crores to profit after tax in FY26.
- A Spanish joint venture for European market access - the 45%-owned CHEMO SMS ENTERPRISES SL, formed in 2021 with Chemo Iberica of Spain, develops products whose Drug Master Files are owned by the JV itself; it delivered first-to-market positioning in Europe for certain anti-diabetic APIs and established a leading position there.
- Two wholly-owned subsidiaries for the next act - SMS Peptides Private Limited (incorporated November 2024) is building a dedicated R&D facility for peptide-based APIs and CRO services, while SMS coLab Private Limited (incorporated December 2025) is a greenfield vehicle for manufacturing pharmaceuticals in new therapeutic categories; neither had begun revenue operations as of late 2025.